Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Background Guideline‐recommended disease‐modifying pharmacological therapies for heart failure (HF) with reduced ejection fraction are underutilized, particularly among elderly patients.
Caroline H. Garred +11 more
doaj +1 more source
Drug treatment of hypertension: focus on vascular health [PDF]
, 2016 Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart
Cameron, Alan C. +2 more
core +1 more source
American Journal of Ophthalmology Case Reports, 2023 Purpose: To report the resolution of subretinal fluid persisting more than a year following retinal detachment surgery resolving with a short term course of mineralocorticoid receptor antagonists use.
Mohamad El Wardani, Marc D. de Smet
doaj +1 more source
Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably! [PDF]
, 2017 No abstract ...
Aspirin Myocardial Infarction Study Research Group +23 more
core +1 more source
Mineralocorticoid receptor antagonists for heart failure [PDF]
Expert Opinion on Pharmacotherapy, 2011 Although mineralocorticoid receptor (MR) antagonists are indicated in systolic heart failure, they are underprescribed in patients with appropriate indications for their prescription and often used in those in whom the evidence for probable benefit is scant.
openaire +4 more sources
Comparison of different strategies to measure medication adherence via claims data in patients with chronic heart failure [PDF]
, 2019 Medication adherence correlates with morbidity and mortality in patients with chronic heart failure (CHF), but is difficult to assess. We conducted a retrospective methodological cohort study in 3,808 CHF patients, calculating adherence as proportion of ...
Griese‐Mammen, Nina +6 more
core +1 more source
Oral Mineralocorticoid-Receptor Antagonists: Real-Life Experience in Clinical Subtypes of Nonresolving Central Serous Chorioretinopathy With Chronic Epitheliopathy. [PDF]
, 2016 PURPOSE: To evaluate the efficacy and safety of oral mineralocorticoid-receptor antagonist (MRa) therapy in three clinical presentations of nonresolving central serous chorioretinopathy (CSCR) with chronic epitheliopathy.
Behar-Cohen, F. +6 more
core +1 more source
Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease [PDF]
International Journal of Molecular Sciences, 2021 Mineralocorticoid receptor antagonists (MRA) are drugs with a potentially broad spectrum of action. They have been reported to have healing effects in many diseases, such as chronic heart failure, hypertension, or nephrotic syndrome. Numerous studies suggest that mineralocorticoid receptor activation is pathogenic and a progression factor of chronic ...
Wiktoria Baran +6 more
openaire +2 more sources
Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
Frontiers in Endocrinology, 2021 ObjectiveTo investigate how often target renin is pursued and achieved in patients with primary aldosteronism (PA) and other low renin hypertension (LRH) treated with mineralocorticoid receptor antagonists (MRAs), as reversal of renin suppression was ...
Yuta Tezuka, Yuta Tezuka, Adina F. Turcu
doaj +1 more source
A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI [PDF]
, 2013 BACKGROUND: Acute kidney injury (AKI) is a frequent condition in hospitalised patients undergoing major surgery or the critically ill and is associated with increased mortality.
Delles, C. +6 more
core +3 more sources